Form 4 for PCVX Vaxcyte, Inc.
Accepted 2026-05-01 17:37:53 ET · period of report 2026-05-01 · accession 0001813798-26-000010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-05-01 17:37 | 2026-05-01 | PCVX | Wassil Jim | COO | S - Sale | $56.83 | -2,250 | 160.7K | -1% | -$127.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-01 | S | D | 2,250 | $56.83 | 160,744 | D | — | — | (F1) The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. (F2) The price reported is a weighted-average price. The shares were sold at prices ranging from $56.425 to $57.26. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |